SRPT Jun 2024 133.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 01:39PM EDT. Market open.
Loading interactive chart...
- Zacks
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.
- GuruFocus.com
Insider Sale: EVP, General Counsel Ryan Brown Sells 38,957 Shares of Sarepta Therapeutics Inc (SRPT)
Ryan Brown, EVP, General Counsel of Sarepta Therapeutics Inc (NASDAQ:SRPT), sold 38,957 shares of the company on June 25, 2024.
- Investor's Business Daily
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded from 68 to 95 Monday. The biotech soared 30% Friday on positive news on its Duchenne Muscular Dystrophy gene therapy. Decades of market research shows that the best stocks often have an 80 or better RS Rating as they begin their biggest runs.
© 2024 Yahoo. All rights reserved.